ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 115 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q2 2020. The put-call ratio across all filers is 1.42 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $120,379,132 | -12.2% | 4,711,512 | -1.4% | 0.32% | -5.6% |
| Q2 2023 | $137,047,380 | +19.6% | 4,778,500 | 0.0% | 0.34% | +18.1% |
| Q1 2023 | $114,540,645 | +59.3% | 4,778,500 | +12.7% | 0.29% | +44.7% |
| Q4 2022 | $71,902,836 | +36.0% | 4,239,554 | +18.8% | 0.20% | +28.4% |
| Q3 2022 | $52,870,000 | -5.7% | 3,567,497 | +0.2% | 0.16% | +2.0% |
| Q2 2022 | $56,052,000 | -44.7% | 3,561,097 | -5.3% | 0.15% | -33.6% |
| Q1 2022 | $101,421,000 | -25.8% | 3,761,900 | +1.8% | 0.23% | -9.8% |
| Q4 2021 | $136,749,000 | -6.0% | 3,694,929 | +21.3% | 0.25% | -8.3% |
| Q3 2021 | $145,504,000 | +42.0% | 3,045,288 | +0.6% | 0.28% | +45.0% |
| Q2 2021 | $102,468,000 | -22.5% | 3,028,000 | -5.5% | 0.19% | -25.7% |
| Q1 2021 | $132,284,000 | -11.7% | 3,203,000 | -7.2% | 0.26% | -16.0% |
| Q4 2020 | $149,783,000 | +153.6% | 3,452,810 | +150.8% | 0.31% | +121.7% |
| Q3 2020 | $59,060,000 | +105.4% | 1,376,675 | +123.8% | 0.14% | +94.4% |
| Q2 2020 | $28,747,000 | – | 615,044 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DFPG INVESTMENTS, LLC | 456,390 | $5,541,000 | 3.62% |
| DAFNA Capital Management LLC | 173,914 | $1,890,000 | 0.65% |
| One68 Global Capital, LLC | 19,861 | $216,000 | 0.47% |
| Diametric Capital, LP | 51,982 | $565,000 | 0.41% |
| ARK Investment Management | 1,383,756 | $15,041,000 | 0.38% |
| EAM Investors, LLC | 52,833 | $574,000 | 0.13% |
| HIGHLINE CAPITAL MANAGEMENT, L.P. | 31,404 | $341,000 | 0.05% |
| Nikko Asset Management Americas, Inc. | 280,548 | $3,050,000 | 0.05% |
| MGO ONE SEVEN LLC | 14,900 | $161,000 | 0.04% |
| Qube Research & Technologies Ltd | 67,702 | $736,000 | 0.02% |